Digestive Disease Week (DDW) 2025

Biomarker-informed molecular guidance improves anti-TNF therapy outcomes in patients with inflammatory bowel disease (IBD), increasing the likelihood of achieving disease control when compared with standard “best care,” as shown in the GUIDE-IBD trial.

The next-generation oral full-spectrum microbiome drug EBX-102-02 appears to have an acceptable safety profile in patients with irritable bowel syndrome with constipation (IBS-C) while yielding improvements in symptom severity, abdominal pain, and stool consistency, according to the results of the phase IIa TrIuMPH* study.

The selective PPARδ* agonist seladelpar continues to demonstrate benefit in patients with primary biliary cholangitis (PBC) in the long-term pooled analysis from the ongoing open-label phase III ASSURE trial.